Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + Chemo + APBSCT in Relapsed NHL
NCT00012051Phase 3Completed
- Sponsor
- Commissie voor Klinisch Toegepast Onderzoek
- Start
- Sep 2000
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of rituximab in B-cell non-Hodgkin lymphoma (2 arms), sponsored by Commissie voor Klinisch Toegepast Onderzoek. Primary endpoint: Overall Survival. Started Sep 2000; status: completed.
02
Drugs
rituximab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00012051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00012051.